Mar 3, 2009 - Teva Pharmaceutical Industries Ltd., today announced that the U.S. FDA has approved an expanded indication for COPAXONE (glatiramer acetate injection) to include the treatment of patients who have experienced a first clinical episode and have magnetic resonance imaging features consistent with multiple sclerosis (MS).
the details can be read here.
No comments:
Post a Comment